{
    "2019-05-23": [
        [
            {
                "time": "",
                "original_text": "中药饮片和保健食品混为一谈？“灵芝第一股”寿仙谷被指涉嫌虚假宣传 欺诈造假",
                "features": {
                    "keywords": [
                        "中药饮片",
                        "保健食品",
                        "虚假宣传",
                        "欺诈造假",
                        "寿仙谷"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "步长制药回复年报问询函 医药行业销售费用和研发投入受关注 问询",
                "features": {
                    "keywords": [
                        "步长制药",
                        "年报问询",
                        "销售费用",
                        "研发投入"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "又一中药注射剂企业收问询函！年入2.64亿的瓜蒌皮注射液被关注 问询",
                "features": {
                    "keywords": [
                        "中药注射剂",
                        "问询函",
                        "瓜蒌皮注射液"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "易明医药去年利润腰斩 两票制后主营药品毛利从76%降至4%",
                "features": {
                    "keywords": [
                        "易明医药",
                        "利润腰斩",
                        "两票制",
                        "毛利率下降"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "步长制药如何花掉80亿销售费？深夜回复可不简单！",
                "features": {
                    "keywords": [
                        "步长制药",
                        "销售费用",
                        "80亿"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业2019q1业绩前瞻-2019q1医药板块整体增长稳健，个股业绩持续分化",
                "features": {
                    "keywords": [
                        "医药生物",
                        "2019q1",
                        "业绩增长",
                        "个股分化"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}